Application form UNIVERSITY OF NOTTINGHAM MEDICAL SCHOOL ETHICS COMMITTEE

Similar documents
The Pathway of Project Approvals. Charlotte Davies- Research and Development Operations Manager

APPLICATION FORM. Application for a Recognised Research Ethics Committee (REC) Opinion on a Clinical Trial on a Medicinal Product for Human Use.

A SHORT GUIDE TO THE PROCEDURE FOR A CLINICAL TRIAL APPLICATION IN THE KINGDOM OF BAHRAIN

STANDARD OPERATING PROCEDURE FOR RESEARCH. 14. Amendments to Research Studies

QUEEN S UNIVERSITY BELFAST. Regulations for Research Involving Human Participants

Primary Care mcta 2013: Guidance for use

Conducting Clinical Trials of Investigational Medicinal Products

Louise Brook Clinical Trials Quality Monitor. Date

I. Purpose. II. Definitions. Last Approval Date

GUIDELINES FOR CONDUCTING CLINICAL TRIALS.

Investigator Site File Index (CTIMP)

Phase 1 studies and The Over- Volunteering Prevention System (TOPS)

Supply of aseptically - prepared doses of IMPs across legal boundaries. Edition 1. December 2017

Writing a Protocol for CTIMPs

R&D Administration Manager. Research and Development. Research and Development. NHS Staff Trust-Wide THIS IS A CONTROLLED DOCUMENT

PREPARING TO RUN A TRIAL

Low/Negligible Risk Research Ethics and Governance Application Guidelines

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Ireland

Author Signature: Date: 11 October 2017 The author is signing to confirm the technical content of this document

Study Files and Filing

Date : Date of start of procedure: Authorisation/ positive opinion :

How to Apply for Ethics (Non-CTIMPs) including Sponsorship

Hospital Authority (HA) Guide on Research Ethics (for Study Site & Research Ethics Committee)

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria

Integrated Research Application System (IRAS) Question-specific guidance Part B Section 3. Exposure to ionising radiation

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL

ANNEX. CHAPTER I General principles

Sponsorship of Clinical Research Studies

SECTION A: APPLICANT/PRINCIPAL INVESTIGATOR:

Regulatory and ethical requirements in medical device studies. Finland

Office for Human Subject Protection. University of Rochester

NORTHERN IRELAND AMBULANCE SERVICE ATTENDANCE MANAGEMENT POLICY

Research Governance Policy and Procedure

Peninsula Medical Practice Recruitment policy

General. Applying for ethical approval from the MoD Research Ethics Committee. R Linton

MEDICINES CONTROL COUNCIL

STP Project Ethical Approval Process

Research Study Close-down and Archiving Procedures

Natural Health Products Directorate (NHPD) Clinical Trial Application and Attestation for Instructions with Sunnybrook specifics

Version Number: 004. On: June 2018 Review Date: June 2021 Distribution: Essential Reading for: Information for: Page 1 of 10

How to put together an IND application

HOSPITAL AUTHORITY (HA) GUIDE

Regulatory Requirements & Recent Changes, including expectations for APIs & IMPs

Page 1 Executive Summary 2 2 Introduction

Title: Department: Approved by: Director, Human Research Review and Compliance

Combined trial of an investigational medicinal product and an investigational medical device

Standard Operating Procedures

The Right Prescription for Working with Investigational Drug Service at BMC

Natural Health Products Directorate (NHPD) Clinical Trial Application and Attestation for Instructions with Sunnybrook specifics

IMP Management and Accountability

Research & Development. J Illingworth and S Moffat. Research, pharmacy and R&D staff

F.No /13-DC (Pt-13A ) Office of Drugs Controller General (India) New Drugs Division

Institutional Review Board for Use of Human and Animal Subjects in Research OIT

Confirming Research Study Capacity and Capability

COOPERATIVE RESEARCH AND EXTERNAL INVESTIGATORS

Trial Master File / Investigator Site File Index Clinical Trials of Investigational Medicinal Products

Good Clinical Practice, GCP. Clinical Trials 101 GCIG CCRN QA

OVERVIEW OF DIRECTIVE 2001/20. Paul Derbyshire. Background & History. Aims of Directive 2001/20

Investigator Site File Index (Medical Devices)

CIR Blood Resource OVERVIEW Use of healthy donor human blood New ethics protocol from 2016

NOTICE. Subject: Stakeholders suggestions/comments on Clinical Trials conductance in India

Rules of Human Experimentation

UNIVERSITY RESEARCH ETHICS COMMITTEE RESEARCH ETHICS POLICY AND PROCEDURES. 8th Edition (2017)

Management and Accountability of Investigational Medicinal Products in the King s Clinical Research Facility

CODE OF PRACTICE FOR RESEARCH

Implications for Investigator Initiated Trials (IITs)- Risk Based Approaches in Managing Clinical Trials

STANDARD OPERATING PROCEDURE FOR RESEARCH. 17. Study Close Down

Standard Operating Procedure

POLICY FOR RESEARCH INVOLVING DRUGS, BIOLOGICS OR DEVICES 6/1/2011

HARROGATE & RURAL DISTRICT AREA PRESCRIBING COMMITTEE (HaRD APC) Application for a new product to be added to the formulary

APPLICATION FOR PERMISSION FOR ANIMAL EXPERIMENTS

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL

A. TRIAL IDENTIFICATION

Postoutline : Radiographer (Radionuclide Imaging)

MEDICINES CONTROL COUNCIL

Date : Date of start of procedure: Authorisation/ positive opinion :

Guide to EU Clinical Trial Application Form

PERFORMANCE IN INITIATING AND DELIVERING CLINICAL RESEARCH INFORMATION SUBMISSION GUIDELINES

RESEARCH GOVERNANCE SITE SPECIFIC ASSESSMENT

MCW Office of Research Standard Operating Procedure

Cancer Vanguard. Biosimilars Trust Policy Template

Ethics Application Overview

Management and Accountability of Investigational Medicinal Products in the King s Clinical Research Facility

ROLE OF THE RESEARCH COORDINATOR Investigational New Drug Application-Sponsor Responsibilities 21CFR Part , subpart D

CHECKLIST: Pre-review

5DGLDWLRQSURWHFWLRQ *XLGDQFHRQPHGLFDO H[SRVXUHVLQPHGLFDODQG ELRPHGLFDOUHVHDUFK (XURSHDQ&RPPLVVLRQ

PART 1 Introduction to Revalidation

Clinical trials from CRA s point of view

Investigational Medicinal Product (IMP) Management Standard Operating Procedure

PHV-3 Version 4 - Non-Interventional Post-Authorisation Safety Studies of Medicinal Products for Human Use

GUIDELINE REGARDING COLLECTION, VERIFICATION, AND SUBMISSION OF THE REPORTS OF ADVERSE EVENTS / REACTIONS OCCURRING IN CLINICAL DRUG TRIALS

STANDARD OPERATING PROCEDURE SOP 410. Set up and Initiation of an Investigator Site

STUDY DOCUMENTS. DOCUMENT NO.: CR007 v4.0. Marise Buçukoğlu ISSUE DATE: 07 MAR 2017 EFFECTIVE DATE: 21 MAR INTRODUCTION

The patient must address the treating physician directly if he/she has any questions or requires information regarding the test results.

Russian Federation. Chapter 12. By Julianna Tabastajewa and Svetlana Rudevich

FACTS YOU NEED TO KNOW UNITED STATES OF AMERICA

annex 3. Template consent form for biobanking

Your statutory duties A reference guide for NHS foundation trust governors

Effective Date: April 19, 2018 TITLE: GUIDELINE FOR RADIATION SAFETY COMMITTEE REVIEW OF HUMAN RESEARCH STUDIES. Table of Contents

SECONDARY EMPLOYMENT POLICY

Transcription:

Application form UNIVERSITY OF NOTTINGHAM MEDICAL SCHOOL ETHICS COMMITTEE In completing this form please refer to the attached Notes of Guidance Application for approval of all studies involving Healthy Human Volunteers only conducted by Staff and Students of the University of Nottingham Please complete in typewritten form one application form, consent form (template attached) and subject's information sheet (template attached), one detailed study proposal and supply 1 one signed hard copy and e-mail 1 copy of as attachments. 1 Title of Project: 2 Names, Position, Department, institution and Qualifications of Investigators: 3 Type of Project: (Please tick appropriate box) a) Classroom procedures: [ ] b) Student project [ ] c) Development of technique: [ ] d) Assessment of new drug or formulation:* [ ] e) Pilot Study: [ ] f) Questionnaire-based study [ ] or community survey g) Commercially funded* [ ] h) Other [ ] *In line with charges being imposed by other Ethics Committees a charge of 250 will be imposed on all commercially funded projects. An additional charge of 100 may be imposed for resubmission or for re-assessing amendments to the original proposal where full committee approval is required and 50 where only chairman's approval is necessary. There shall be no charge for research funded by the NHS, by other government funding sources such as the Research Councils, by charities and by educational grant giving bodies. Faculty of Medicine & Health Sciences Page 1 7/23/2013

4a Summary of Experimental Protocol - Please give details below (no longer than this side of A4 ) under the following headings: - 1. Background. 2. Aims (to include hypothesis to be tested), 3. Experimental protocol and methods, 4. Measurable end points/statistical power of the study. 5. Key references. This section must be completed. This is in addition to a more detailed project proposal/protocol which should be attached to this application. Please use 10pt typeface. Do not go over the page Faculty of Medicine & Health Sciences Page 2 7/23/2013

4b Lay Summary of project (in lay words):(maximum 200 words) Summaries which include language which is too technical for lay members of the Committee will be rejected. 5 Duration of Study: 6 Location of study: Proposed starting date: Proposed finishing date: 7 Description and number of volunteers to be studied: 8 Will written consent be obtained from all volunteers? Please give the name, status and relevant qualifications of the person who will give a verbal explanation and obtain consent. 9 Will a disturbance allowance be offered? If Yes, give rate (*delete as appropriate) *Per day: *Per procedure: *Per Study: *Give the maximum allowance payable to a volunteer: 10 Will a medical supervisor be present: If Yes, give name and qualifications: 11a Does the study involve the exposure of the patient to radioactive materials? If your project involves the administration of radioisotopes your attention is drawn to note 10 a) in the attached notes of guidance. Radiological Practitioner/ARSAC certificate holder Name Signature* What is the total effective dose *The Radiological Practitioner/ARSAC certificate holder must sign to accept responsibility for the radiological procedure listed above. Faculty of Medicine & Health Sciences Page 3 7/23/2013

It is the responsibility of the investigator to ensure that the total exposure of a volunteer to ionising radiation will not exceed 5 msv over any 12 month period. The Radiation Protection Adviser (RPA) must sign below to confirm that the dose estimate is satisfactory and that the appropriate arrangements are in place for undertaking the procedure. RPA Name Signature Date 11b Does the study involve the exposure of the patient to X-rays? Type of procedure: All research involving radiology must be submitted and approved by the Clinical Director for Radiology. RPA Name Signature* What is the total effective dose Clinical Director Name Signature Date 12 Will participant s General Practitioners be told about the study? This would be regarded as essential if the study includes consumption of drugs or novel chemical entities or if you are recommending that the volunteer should see their GP as a result of the study. If no please justify 13a 1. If the procedure involves any intervention or treatment (blood sampling, biopsy, i.v injections, manipulation etc) does the practitioner performing this intervention or treatment have personal profession negligence insurance 2. If the procedure involves new drug, formulation or device, will full insurance cover be provided by the sponsoring drug firm? If Yes, See Guidelines Note 1: Insurance Proof of indemnity and a copy of the company s certificate of insurance should be forwarded for consideration at the same time as the application and protocol. Faculty of Medicine & Health Sciences Page 4 7/23/2013

13b FUNDING Will there be any material benefits from the study for the Department or individual investigator? (E.g. equipment, research salaries, consumables etc) If yes please specify in general terms what the benefits will be: 13c Trust R&D Does the study involve any staff who hold a contract with the hospital trust?(this does not include investigators with an honorary contract with the NHS but does include staff whose salary is provided by the NHS eg Nurse, radiographer, physiotherapist) Will the study use any space/facilities/ resources belonging to the hospital trust? (eg Xray, pathology, blood tests other than those used to screen volunteers). If you answer yes to both of the above questions please complete and submit the online QMC Trust R&D form available at the following links: http://intranet/sqmcinfo/divisions/others/r&d/index.htm or http://www.qmc.nhs.uk/research/index.htm. 14a Drugs or other substances to be administered (including placebo and comparators) Drug name: Generic Name: Proprietary Name: Formulation: Dose: Frequency: Route: Possible complications (append details if necessary) Please tick where appropriate CSM status Clinical Trials Authorisation (CTA) Product Licence (PL) For drugs with a product licence please append a copy of the relevant data sheet. For drugs with a CTA, please append a statement detailing present knowledge of the drug action, adverse effects, long and short-term safety. The number of the PL, CTA MUST be included. If a new drug formulation is being studied an explicit statement as to the UK licensing status of the product is required. For unlicensed products then information should be given as to its licensing status in other countries and appropriate safety data should be submitted. Arrangements for the supply, storage and dispensing of trial drugs must be discussed with the Senior Pharmacist at the relevant hospital who must sign below. Faculty of Medicine & Health Sciences Page 5 7/23/2013

14b Will any drug used be stored in the Pharmacy and dispensed to a prescription written in red? If No, please explain why: Signature of Pharmacist.. Printed Name NB THIS MUST BE OBTAINED 15 Does the project involve painful/dangerous or invasive procedures on volunteers? Please outline risks and degree of discomfort 16 Will blood samples or other specimens be required? If so, will written informed consent be obtained? What volume will be required and over what duration?* *Studies involving venepuncture only, where the information generated is of no prognostic significance, will be approved by Chairman's action provided no more than a total of 500mls of blood is taken over a 6 month period and no more than 200mls is taken on a single occasion. Applicants need to submit 1 copy of this form and other documentation with a covering letter to the Chairman. 17 How will the subjects be chosen? Please specify what criteria will be used and which groups you wish to target. Please include a copy of your proposed poster or advert 18 Describe how possible participants will be approached? Please refer to note 9 in the Guidelines. Please specify whether posters will be used and where they will be placed. Faculty of Medicine & Health Sciences Page 6 7/23/2013

**** If your study is community-based or epidemiological study please answer the following questions (19-21) 19 What sources of information will be included? (tick any that apply) Personal interview Postal questionnaire** [ ] Hospital records [ ] GP records [ ] Occupational records [ ] Other, describe ** Please submit a copy of your proposed questionnaire if you are a student please make sure your supervisor has reviewed and approved it. 20 Whose permission will be sought to access this information (eg GP, consultant)? 21 For interview surveys only: Please indicate who will do interviews (eg Students, research nurses etc) Please submit an interview schedule including an outline of questions or topics to be discussed. 22 What ethical problems do you foresee in this project? Any other relevant information? DECLARATION: I will inform the Medical School Ethics Committee as soon as I hear the outcome of any application for funding for the proposed project and/or if there are any significant changes to this proposal. I have read the notes to the investigators and clearly understand my obligations as to the rights, welfare and dignity of the subjects to be studied, particularly with regard to the giving of information and the obtaining of consent. Signature of Lead Investigator: Date: **Nb If you are student your supervisor must sign this form otherwise it will be rejected Name and address for correspondence with applicant: Faculty of Medicine & Health Sciences Page 7 7/23/2013

Submission of protocols for consideration CHECK LIST 1 PAPER COPY WITH ALL RELEVANT ORIGINAL SIGNATURES OF Completed form signed by the lead investigator or supervisor of project. Short study protocol/project proposal Indemnity where applicable Information Sheet Consent Form Poster or advert to be used. Letters of permission from outside institutions where applicable Copy of proposed questionnaire where applicable Outline of interviews or focus group discussions where applicable Drug data sheets where applicable must be submitted to: Mrs Louise Sabir Ethics Committee Secretary Division of Therapeutics and Molecular Medicine D Floor, South Block Queen s Medical Centre Nottingham NG7 2UH 1 ELECTRONIC COPY E-MAILED AS ATTACHMENTS TO: louise.sabir@nottingham.ac.uk at least two weeks before the meeting. This is necessary to ensure that all members of the Committee can adequately review the application. Applications received after this time will be held over until the following meeting. Approval cannot be given to protocols by Chairman's action. Faculty of Medicine & Health Sciences Page 8 7/23/2013